FASINUMAB (REGN475), AN ANTINERVE GROWTH FACTOR MONOCLONAL ANTIBODY, FOR THE TREATMENT OF ACUTE SCIATIC PAIN: RESULTS OF A PROOF-OF-CONCEPT STUDY

Fasinumab (REGN475), an antinerve growth factor monoclonal antibody, for the treatment of acute sciatic pain: results of a proof-of-concept study

Paul J Tiseo,1 Haobo Ren,2 Scott Mellis3 1Pharmacovigilance Operations and Risk Management, Regeneron bovi-shield gold fp 5 l5 Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Biostatitics, Regeneron Pharmaceuticals, Inc., Basking Ridge, NJ, USA; 3Translational Medicine and Predictive Medicine, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA Objecti

read more